AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25392319 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Interferon beta (IFNb)
Number of subjects: 180
Study 25392319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 25392319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biomarkers (CASP2/IRF4/IRF6)
Number of subjects: 180
Study 25392319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biomarkers (CASP2/IL10/IL12Rb1)
Number of subjects: 180
Study 23522849 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 271
Study 20558036 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug with no side effects, no additional visit required, balanced information provided, results in the public domain, project approved by a research ethics committee.
Number of subjects: 1277
Study 20558036 — intervention group
Group type: COMPARATOR
Intervention: Destruction of blood samples at the end of the project, use of placebo controls, random allocation to study arms.
Number of subjects: 1277
Study 20558036 — intervention group
Group type: COMPARATOR
Intervention: Origin of funds, financial reward, need to complete a questionnaire, clinical vs. economic purpose of the study.
Number of subjects: 1277
Study 18578802 — intervention group
Group type: EXPERIMENTAL
Intervention: Community nursing services (home visits)
Number of subjects: 46
Study 16544149 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-anal pudendal nerve stimulation daily at home with a portable home unit
Number of subjects: 48
Study 16544149 — intervention group
Group type: COMPARATOR
Intervention: Endo-anal electrical stimulation under supervision in physiotherapy department
Number of subjects: 48
Study 12842509 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 1090
Study 12842509 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass (CABG)
Number of subjects: 1090
Study 10666428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1208
Study 10666428 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1208
Study 8558203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (5 mg/kg bolus over 3 hours followed by 15 mg/kg infusion over 24 hours) plus paclitaxel (200 mg/m2 over 3 hours)
Number of subjects: 26
Study 1775272 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-oxygenation (group A)
Number of subjects: 40
Study 1775272 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique with bubble oxygenator (group B)
Number of subjects: 40
Study 6353927 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg relaxin
Number of subjects: 0
Study 6353927 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg relaxin
Number of subjects: 0
Study 6353927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30770754 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMP-AA2
Number of subjects: 48
Study 30770754 — intervention group
Group type: COMPARATOR
Intervention: L-AA
Number of subjects: 48
Study 26945913 — intervention group
Group type: EXPERIMENTAL
Intervention: Home tele-rehabilitation system
Number of subjects: 0
Study 26945913 — intervention group
Group type: COMPARATOR
Intervention: Post-trial rehabilitation (control group)
Number of subjects: 0
Study 26738667 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom onset-to-balloon time (SBT)
Number of subjects: 2056
Study 26738667 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon time (DBT)
Number of subjects: 2056
Study 26738667 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk factors (anterior infarction, reference vessel diameter, lesion minimum lumen diameter, hyperlipidemia, current smoking)
Number of subjects: 2056
Study 26738667 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular perfusion measures (MBG 0/1 and STR <30%)
Number of subjects: 2056
Study 26021535 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal (TP) approach
Number of subjects: 100
Study 26021535 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal (RP) approach
Number of subjects: 100
Study 21331637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (5% sodium fluoride, Duraphat(®), Colgate) applied monthly for 6 months
Number of subjects: 110
Study 21331637 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control) applied monthly for 6 months
Number of subjects: 110
Study 19458299 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight-tip Tenckhoff catheter with an artificial subcutaneous swan neck (TC)
Number of subjects: 39
Study 19458299 — intervention group
Group type: COMPARATOR
Intervention: Conventional double-cuff straight-tip swan-neck catheter (SN)
Number of subjects: 39
Study 19458299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TC and SN)
Number of subjects: 39
Study 17635844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.87 mg triptorelin depot i.m. followed by daily s.c. injections of saline
Number of subjects: 182
Study 17635844 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose daily buserelin (0.5 mg initially, reduced to 0.25 mg)
Number of subjects: 182
Study 15682929 — intervention group
Group type: EXPERIMENTAL
Intervention: Gincosan (320mg/day, containing 120mg Ginkgo biloba and 200mg Panax ginseng)
Number of subjects: 30
Study 15682929 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 30
Study 11579354 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of oral conjugated estrogens (Premarin) per day for 4 to 6 weeks
Number of subjects: 24
Study 11579354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9848785 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/d)
Number of subjects: 20
Study 9848785 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (100 mg/d)
Number of subjects: 20
Study 9848785 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/d) + Indomethacin (75 mg twice a day)
Number of subjects: 20
Study 9848785 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (100 mg/d) + Indomethacin (75 mg twice a day)
Number of subjects: 20
Study 7814791 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal exercise conditioning program (3 months)
Number of subjects: 60
Study 7814791 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal exercise conditioning program (3 months and 12 months)
Number of subjects: 60
Study 7814791 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n = 23, mean age 68 ± 5 years)
Number of subjects: 60
Study 7814791 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal exercise conditioning program
Number of subjects: 60
Study 2354691 — intervention group
Group type: EXPERIMENTAL
Intervention: Toasted Am proteins (20%, 30%, and 50% replacement of M proteins)
Number of subjects: 0
Study 2354691 — intervention group
Group type: COMPARATOR
Intervention: Maize (M) alone
Number of subjects: 0
Study 2354691 — intervention group
Group type: EXPERIMENTAL
Intervention: Am alone
Number of subjects: 0
Study 6161868 — intervention group
Group type: EXPERIMENTAL
Intervention: Farial nose drops
Number of subjects: 64
Study 6161868 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline-containing nose drops
Number of subjects: 64
Study 28967201 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin with 150 mg aclatonium once daily for 8 weeks
Number of subjects: 92
Study 28967201 — intervention group
Group type: COMPARATOR
Intervention: 5 mg solifenacin with placebo once daily for 8 weeks
Number of subjects: 92
Study 26750772 — intervention group
Group type: EXPERIMENTAL
Intervention: CO-OP training
Number of subjects: 11
Study 26750772 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPUTER training
Number of subjects: 11
Study 25382452 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (titrated from 3.125 mg twice daily to 6.25 mg twice daily)
Number of subjects: 0
Study 25382452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25382452 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 24938848 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of additional noninvasive cardiac event monitoring with an R‐test device
Number of subjects: 49
Study 24938848 — intervention group
Group type: EXPERIMENTAL
Intervention: Any investigative modality for PAF detection
Number of subjects: 49
Study 23237631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol dosing algorithm based on demographic, clinical, and pharmacogenetic variables (VKORC1, CYP2C9, CYP4F2, ApoE)
Number of subjects: 240
Study 23237631 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) with scheduled and adjusted acenocoumarol dose following common clinical practice
Number of subjects: 240
Study 23237631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol dosing algorithm
Number of subjects: 240
Study 21290841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-assisted anesthesia (periprostatic nerve plexus block and acupuncture on bilateral Zusanli ST 36) in group A
Number of subjects: 105
Study 21290841 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple periprostatic nerve plexus block) in group B
Number of subjects: 105
Study 17876425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam (5 mg for those under 65 years, 2.5 mg for those aged 65 years or more)
Number of subjects: 40
Study 17876425 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 40
Study 16230678 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI FU 225 mg/m2/d for 5 d/wk for six cycles during RT
Number of subjects: 0
Study 16230678 — intervention group
Group type: COMPARATOR
Intervention: Weekly cisplatin 40 mg/m2
Number of subjects: 0
Study 11988242 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b 250 microg administered every other day
Number of subjects: 188
Study 11988242 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1a 30 microg administered once a week
Number of subjects: 188
Study 10560984 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy young men
Number of subjects: 25
Study 7569506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response information to support drug registration (especially dose/toxicity relationships)
Number of subjects: 0
Study 7569506 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies in support of special populations; Geriatrics
Number of subjects: 0
Study 7569506 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH Draft Guideline 3 on the extent of population exposure required to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions
Number of subjects: 0
Study 1978233 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol (1‐3 mg daily)
Number of subjects: 40
Study 1978233 — intervention group
Group type: COMPARATOR
Intervention: metoprolol (100‐300 mg daily in two divided doses)
Number of subjects: 40
Study 336412 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LH-RH)
Number of subjects: 8
Study 336412 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 8
Study 336412 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 8
Study 336412 — intervention group
Group type: COMPARATOR
Intervention: All treatments (LH-RH, hCG, and placebo)
Number of subjects: 8
Study 30578650 — intervention group
Group type: COMPARATOR
Intervention: Free-handed surgery (FH)
Number of subjects: 33
Study 30578650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot-drill guided surgery (PG)
Number of subjects: 33
Study 30578650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully guided surgery (FG)
Number of subjects: 33
Study 29119732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Group R, n=30)
Number of subjects: 60
Study 29119732 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (Group W, n=30)
Number of subjects: 60
Study 29119732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Group R)
Number of subjects: 60
Study 29119732 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (Group W)
Number of subjects: 60
Study 25259552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (11°C)
Number of subjects: 26
Study 25259552 — intervention group
Group type: COMPARATOR
Intervention: Tepid water immersion (26°C)
Number of subjects: 26
Study 22985692 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg (three-times/day)
Number of subjects: 273
Study 22985692 — intervention group
Group type: COMPARATOR
Intervention: Inhaled tobramycin nebulizer solution (TNS) 300 mg (twice/day)
Number of subjects: 273
Study 21219582 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise
Number of subjects: 27
Study 21219582 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 27
Study 19101221 — intervention group
Group type: EXPERIMENTAL
Intervention: VASP-guided group (n = 215)
Number of subjects: 429
Study 19101221 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 214)
Number of subjects: 429
Study 16764551 — intervention group
Group type: COMPARATOR
Intervention: Placebo techniques developed to mimic spinal manipulative therapy
Number of subjects: 25
Study 15232758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal application of prostaglandin E2 (PGE2)
Number of subjects: 262
Study 11713618 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 10
Study 11713618 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg and 5 mg
Number of subjects: 10
Study 11713618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (conditioned dentin)
Number of subjects: 24
Study 9522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (conditioned dentin)
Number of subjects: 24
Study 9522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Sprint (conditioned dentin)
Number of subjects: 24
Study 9522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (unconditioned dentin)
Number of subjects: 24
Study 9522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (unconditioned dentin)
Number of subjects: 24
Study 9522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Sprint (unconditioned dentin)
Number of subjects: 24
Study 8698034 — intervention group
Group type: EXPERIMENTAL
Intervention: High interpersonal stress condition
Number of subjects: 0
Study 8698034 — intervention group
Group type: COMPARATOR
Intervention: Low interpersonal stress condition
Number of subjects: 0
Study 8698034 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study 2711967 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of exercise at 25 W above lactate threshold (ALT)
Number of subjects: 10
Study 2711967 — intervention group
Group type: COMPARATOR
Intervention: 20 minutes of exercise at 25 W below lactate threshold (BLT)
Number of subjects: 10
Study 1089913 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.028 to 0.111 mg/kg)
Number of subjects: 10
Study 31795875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mA stimulation bilaterally over M1 (anode on the right M1 and cathode on the left M1)
Number of subjects: 15
Study 31795875 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 31166680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg once daily)
Number of subjects: 563
Study 28760794 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger and single vitrified-warmed blastocyst transfer in a subsequent hCG triggered natural menstrual cycle
Number of subjects: 424
Study 28760794 — intervention group
Group type: COMPARATOR
Intervention: hCG trigger and single blastocyst transfer in the fresh (stimulated) cycle
Number of subjects: 424
Study 25771895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 0
Study 25771895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23749405 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg U100 (0.4 U/kg)
Number of subjects: 33
Study 23749405 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg U200 (0.4 U/kg)
Number of subjects: 33
Study 23749405 — intervention group
Group type: COMPARATOR
Intervention: IDeg U200
Number of subjects: 33
Study 23749405 — intervention group
Group type: COMPARATOR
Intervention: IDeg U100
Number of subjects: 33
Study 21525194 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides 2.5 g
Number of subjects: 427
Study 21525194 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides 5.0 g
Number of subjects: 427
Study 21525194 — intervention group
Group type: COMPARATOR
Intervention: Galactooligosaccharides 0 g (Control)
Number of subjects: 427
Study 19561369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates intervention (15 sessions of Pilates)
Number of subjects: 28
Study 19561369 — intervention group
Group type: COMPARATOR
Intervention: No Pilates intervention (control group)
Number of subjects: 28
Study 16788276 — intervention group
Group type: EXPERIMENTAL
Intervention: Notified group (n=157)
Number of subjects: 329
Study 16788276 — intervention group
Group type: COMPARATOR
Intervention: Non-notified group (n=172)
Number of subjects: 329
Study 16788276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype ALDH2*1/*1
Number of subjects: 329
Study 16788276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype ALDH2*1/*2
Number of subjects: 329
Study 15446780 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention directed to change prescribing
Number of subjects: 61
Study 15446780 — intervention group
Group type: COMPARATOR
Intervention: Practice groups participating in information exchange (n = 14)
Number of subjects: 61
Study 15446780 — intervention group
Group type: COMPARATOR
Intervention: Practice groups with a formulary (22 groups)
Number of subjects: 61
Study 15446780 — intervention group
Group type: COMPARATOR
Intervention: Practice groups using feedback data (22 groups)
Number of subjects: 61
Study 11530125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg followed by misoprostol 400 microg orally (group 1)
Number of subjects: 80
Study 11530125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg followed by misoprostol 800 microg vaginally (group 2)
Number of subjects: 80
Study 9404564 — intervention group
Group type: EXPERIMENTAL
Intervention: High complement activation group
Number of subjects: 22
Study 9404564 — intervention group
Group type: COMPARATOR
Intervention: Low complement activation group
Number of subjects: 22
Study 9404564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera obtained half a year before the season
Number of subjects: 22
Study 12959295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine with grapefruit juice (200 ml double strength)
Number of subjects: 8
Study 12959295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine with quercetin (400 mg)
Number of subjects: 8
Study 12959295 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine alone
Number of subjects: 8
Study 3126890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (n = 32)
Number of subjects: 92
Study 3126890 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy (n = 30)
Number of subjects: 92
Study 3126890 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (n = 30)
Number of subjects: 92
Study 3126890 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (n = 20)
Number of subjects: 92
Study 30119073 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 58
Study 30119073 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 28350652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (topical application during surgery)
Number of subjects: 322
Study 28350652 — intervention group
Group type: COMPARATOR
Intervention: Control (no mitomycin C)
Number of subjects: 322
Study 25015650 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RAT) - 3 conventional therapy sessions and 2 robot-assisted sessions per week over 8 weeks
Number of subjects: 16
Study 25015650 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy - 5 sessions per week over 8 weeks
Number of subjects: 16
Study 23618380 — intervention group
Group type: EXPERIMENTAL
Intervention: High tertile immune metagene expression in highly proliferative tumors
Number of subjects: 1954
Study 23618380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tertile expression of any one of the three immune metagenes in highly proliferative tumors
Number of subjects: 1954
Study 21205399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oportunidades food supplement (OFS)
Number of subjects: 224
Study 21205399 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered milk (PM)
Number of subjects: 224
Study 21205399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 224
Study 18505372 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral clodronate (Bonefos) daily over 3 years
Number of subjects: 5157
Study 18505372 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5157
Study 12628950 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 291
Study 12628950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 12628950 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (in patients with impaired FPG)
Number of subjects: 291
Study 12628950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with impaired FPG)
Number of subjects: 291
Study 10817062 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent HPV16 infection
Number of subjects: 74447
Study 10817062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia grade III and cervical cancer (CIN III+)
Number of subjects: 74447